Narita Yukiya, Muro Kei
a Department of Clinical Oncology , Aichi Cancer Center Hospital , Nagoya , Japan.
Expert Opin Drug Saf. 2017 Mar;16(3):319-327. doi: 10.1080/14740338.2017.1273348. Epub 2016 Dec 25.
The Cancer Genome Atlas Research Network recently proposed a molecular classification for gastric cancer (GC) into four subtypes based on comprehensive evaluation. While the mechanisms of molecular targeted therapies in GC were confirmed by multiple clinical studies, only a limited number of therapeutics for GC have been approved to date. Areas covered: In this systematic review of the available literature, we discuss the completed and ongoing clinical trials of molecular targeted therapies in patients with GC, with a focus on their efficacy and safety profiles. Expert opinion: Results of recent studies clearly demonstrated that trastuzumab and ramucirumab, monoclonal antibodies (mAbs) against human epidermal growth factor receptor 2 (HER2) and vascular endothelial growth factor (VEGF), respectively, improved overall survival (OS) in GC with manageable safety profiles. Careful surveillance of ongoing clinical trials and timely profiling and monitoring of genetic signatures are imperative to establish a strong foundation for precision medicine in GC.
癌症基因组图谱研究网络最近基于综合评估提出了一种将胃癌（GC）分为四种亚型的分子分类方法。虽然多项临床研究证实了胃癌分子靶向治疗的机制，但迄今为止，获批用于胃癌治疗的药物数量有限。涵盖领域：在对现有文献的这项系统评价中，我们讨论了针对胃癌患者的分子靶向治疗已完成和正在进行的临床试验，重点关注其疗效和安全性。专家意见：近期研究结果清楚地表明，曲妥珠单抗和雷莫西尤单抗，分别作为针对人表皮生长因子受体2（HER2）和血管内皮生长因子（VEGF）的单克隆抗体（mAbs），在胃癌中改善了总生存期（OS），且安全性可控。密切监测正在进行的临床试验，并及时分析和监测基因特征，对于为胃癌精准医学奠定坚实基础至关重要。
